Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma Robert Frank Cornell, Parameswaran Hari, Mei-Jie Zhang, Xiabao Zhong, Jonathan Thompson, Timothy S. Fenske, Mary M. Horowitz, Richard Komorowski, Jeanne Palmer, Marcelo C. Pasquini, J. Douglas Rizzo, Wael Saber, Mathew Thomas, William R. Drobyski Biology of Blood and Marrow Transplantation Volume 19, Issue 9, Pages 1368-1373 (September 2013) DOI: 10.1016/j.bbmt.2013.06.017 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Transplantation outcomes in all patients with and without ES. Cumulative incidence of transplantation-related mortality (TRM) and relapse are depicted in panels A and B. Probability of progression-free survival and overall survival are shown in panels C and D. Biology of Blood and Marrow Transplantation 2013 19, 1368-1373DOI: (10.1016/j.bbmt.2013.06.017) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Transplantation outcomes in multiple myeloma patients with and without ES. Cumulative incidence of transplantation-related mortality (TRM) and relapse are depicted in panels A and B. Probability of progression-free survival and overall survival are shown in panels C and D. Biology of Blood and Marrow Transplantation 2013 19, 1368-1373DOI: (10.1016/j.bbmt.2013.06.017) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions